Liberty Health Sciences Doubles Cultivation Capacity With Expansion of Liberty Health Sciences 360º Innovation Campus

24 Hour Delivery Expanded State Wide

Real Time Delivery Information Provided for Greater Convenience

Five Additional Leases Signed for Cannabis Education Center Locations

Mary's Medicinals Available in all Stores

TORONTO, Aug. 7, 2018 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertycec.com ("Liberty" or the "Company"), a provider of high quality pharmaceutical grade cannabis, announced today that it has doubled its cultivation space in Florida with production commencing at its Liberty Health Sciences 360 Innovation Campus (the "360 Campus") in Gainesville in response to the growing demand by Florida patients. The Company received permission to commence production at the 360 Campus while a retrofit of the facilities is being completed. The Company's Chestnut Hill facility continues to operate at full capacity.

The expansion will increase Liberty's production capacity in the state by an additional 20,000 sq. feet, bringing the total capacity to 41,200 sq. feet. This initial phase of the 360 Campus will be used for the cultivation of premium grade cannabis along with R&D for future genetic study programs.

The next phase of the previously announced retrofit program is scheduled to be completed in November and will add an additional 80,000 sq. feet, which will result in Liberty having the largest production capacity of any medical marijuana producer in Florida. Once the retrofit is fully completed and on-line in early 2019, the Company's production capacity will increase to approximately 225,000 sq. feet.

The new cultivation space is fully operational and environmentally controlled with sophisticated irrigation systems, grow lighting, air filtration exchange, CO2 dosing, and heating and cooling to ensure maximum production of the marijuana plant.

"Our new cultivation expansion initiative is in direct response to the increased customer demand for our products and unparalleled customer service experience," said George Scorsis, CEO of Liberty Health Sciences. "I am proud of our team and our ability to be responsive in real-time to our customers as we continue to provide the best care possible across the state of Florida. This major leap in output will put us well ahead of the competition as we lead the way in commercial horticulture and pharmaceutical grade product development."

To expedite the expansion of Liberty's reach and ensure statewide coverage of its valued customers the Company has also expanded its one-day delivery hub services. All deliveries will now have a turnaround of 24-hours or less throughout the entire state of Florida. To compliment state-wide services, the Company has implemented cutting-edge software to optimize delivery routes, reduce wait time and enhance customer experience. Customers will now receive text message alerts on their mobile devices when their orders are close, keeping them informed, improving delivery anticipation, and reducing missed deliveries.

The Company is also pleased to announce that it has five more leases in place for Cannabis Education Centers including: Boca Raton, Gainesville, Winterhaven, Palm Harbor and Sarasota.

"Liberty's commitment to provide all Florida residents with convenient access to the best cannabis products and some of the industry's best educational resources starts with the expansion of our Cannabis Education Centers and new and exciting initiatives," said Scorsis. "We will continue to expand and upgrade our production line and find resourceful ways to supply all Florida residents with convenient access."

In accordance with the Company's rapidly expanding presence in Florida, production of Liberty's newest and highly anticipated offering to consumers, Mary's Medicinals, has commenced production. The entire award-winning line of innovative Mary's products will soon be available in all of Liberty's Cannabis Education Centers (CEC). Products will include: transdermal patches, transdermal gel pens, topicals, capsules, tinctures and vape pens.

"Thanks to our partnership with Liberty, we are excited to officially bring Mary's unique delivery methods like the transdermal patch and transdermal gel pen, as well as our robust patient-focused educational materials and programs to Florida," said Lynn Honderd, CEO of Mary's Medicinals. "With an increasing understanding of the effects of cannabinoids, patients can now tailor their cannabinoid consumption to the type of relief they need."

About Liberty Health Sciences Inc.

Liberty Health Sciences Inc. operates in cannabis markets focusing on improving the lives of our consumers. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities while keeping consumers' well-being at the forefront of what we do. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to consumers. For more information, please visit www.libertycec.com  

About Mary's Medicinals

Best known as the developer of the award-winning transdermal patch, Mary's Medicinals is a wellness company innovating at the intersection of engineering, technology, and horticulture. All Mary's Medicinals products have the Seal of Approval from The Realm of Caring. For more information, please visit www.marysmedicinals.com, like Mary's Medicinals on Facebook and follow @Marysmedicinals on Twitter and Instagram.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the anticipated timing and completion of the retrofit, production capacities and square footage, the receipt of all necessary approvals, the completion of additional Cannabis Education Centers, the production and sale of edible products in Florida, expected state approval of edibles, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

Media Contact: Dwain Schenck, 203-223-5230, [email protected]